iBio Inc (NYSEAMERICAN: IBIO) is rocketing for the top in the market this morning, and for good reason. The FDA has given a nod to convalescent plasma for use in treating COVID-19 patients, exciting investors. Here’s what’s going on:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
IBIO Rallies On Convalescent Plasma News
iBio has been working on convalescent plasma products since 2011, when it announced the successful production of human plasma proteins. These efforts are boding well with the investing community this morning for good reason.
The FDA recently gave an emergency use nod to convalescent plasma as a potential way to treat COVID-19. Of course, that’s good news for any company in the convalescent plasma space, and IBIO is indeed on that list.
IBIO In COVID-19
IBIO has been a stock to watch closely in the COVID-19 space. The company was one of the earliest to announce that it was developing a COVID-19 vaccine, and now, it’s looking like a play on the treatment side of the coin as well.
At the moment, iBio is currently working on two COVID-19 vaccines. While there are arguments that the company will not be first to market, and I agree with those arguments, the long-term implications of a COVID-19 vaccine could be overwhelmingly positive. Nonetheless, I’ve already made that argument. Read more on the topic here. Nonetheless, when it comes to vaccine plays, IBIO is a strong one.
Nonetheless, the company is now playing on both sides of the field. Not only is it developing what I believe will be successful revenue drivers in COVID-19 vaccination, it now has a product that will likely prove to be effective in the treatment of COVID-19.
The Need For Vaccines And Treatments Will Be Long Term
This is overwhelmingly positive news for IBIO, both in the short term and long term views. Short term, the excitement is likely to drive tremendous growth as investor excitement takes hold, but the long term is where the real excitement is.
The fact of the matter is that coronaviruses are nothing new. It’s the same type of virus that causes the common cold. Nonetheless, we don’t have a vaccine for the cold. That’s because navigating this virus can be difficult.
Nonetheless, even if vaccine development does happen, it doesn’t mean that COVID-19 will cease to exist. The fact of the matter is that we already have a flu vaccine, but the flu kills tens of thousands of people per year as we have not been able to irradicate it.
As a result, I believe that there will be a long-term need, not only for vaccines, but for treatments. With IBIO developing two vaccine candidates for COVID-19, and now coming to light as a strong treatment play, the stock is one that simply should not be ignored.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story
Join our free mailing list below to receve real-time news alerts!